Home > Boards > US Listed > Medical - Drugs > GlaxoSmithKline (GSK)

Drugmakers to join forces to make millions of

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
RNsidersbuying Member Profile
 
Followed By 34
Posts 3,044
Boards Moderated 1
Alias Born 07/26/10
160x600 placeholder
Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece Dow Jones News - 6/14/2019 8:04:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2019 1:32:53 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/7/2019 6:38:58 AM
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options Business Wire - 6/6/2019 5:15:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2019 6:22:29 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/3/2019 11:12:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 5/31/2019 2:05:17 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/24/2019 6:27:25 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2019 9:58:51 AM
Thermo Fisher to Buy Ireland API Plant From GlaxoSmithKline Dow Jones News - 5/16/2019 6:40:00 AM
Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK PR Newswire (US) - 5/16/2019 5:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2019 4:35:04 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/13/2019 4:06:10 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/8/2019 2:03:27 PM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 5/2/2019 4:16:42 PM
GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial Dow Jones News - 5/2/2019 12:59:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/2/2019 12:49:25 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 1:38:47 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 1:19:50 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/1/2019 11:27:14 AM
GlaxoSmithKline Reports Growing Turnover and Profit in 1Q, Beating Market Expectations Dow Jones News - 5/1/2019 7:58:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/29/2019 8:28:21 AM
FDA Approves GlaxoSmithKline's Treatment for Pediatric Patients with Lupus Dow Jones News - 4/26/2019 4:31:00 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 4/26/2019 1:50:27 PM
GlaxoSmithKline Subsidiary Gets Positive Opinion for HIV Drug Dow Jones News - 4/26/2019 12:00:00 PM
RNsidersbuying   Wednesday, 10/22/14 02:32:03 PM
Re: None
Post # of 137 
Drugmakers to join forces to make millions of Ebola vaccine doses
BY BEN HIRSCHLER
LONDON Wed Oct 22, 2014 2:18pm EDT

(Reuters) - Leading drugmakers plan to work together to speed up the development of an Ebola vaccine and hope to produce millions of doses for use next year.

U.S. firm Johnson & Johnson said on Wednesday that it aims to produce at least 1 million doses of its two-step vaccine next year and has already discussed collaboration with Britain's GlaxoSmithKline, which is working on a rival vaccine.

The economics of an Ebola vaccine are still unclear but drug companies with an eye on their reputations are under pressure to respond to the major international health crisis now ravaging one of the poorest corners of Africa.

J&J's head of research Paul Stoffels said it was important to have several experimental vaccine candidates in development, since it is not clear which ones will work, but resources could in future be focused on one clear winner.

GSK's chief executive Andrew Witty told reporters on Wednesday that a meeting of experts in Geneva this week would discuss ways to ensure that all companies, including those with no direct involvement in the Ebola work, pulled together to help remove supply bottlenecks.


http://www.reuters.com/article/2014/10/22/us-health-ebola-johnson-johnson-idUSKCN0IB0N420141022

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist